← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-11 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicstaleNew Approaches to Neuroblastoma…Phase 2

Universal Donor (UD, Universal Donor, Universal Donor (UD) TGFβi NK Cells)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleChinese PLA General HospitalPhase 2

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells (Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNationwide Children's HospitalPhase 2

Universal donor derived CD33 CAR-NK (Universal donor derived CD33 CAR-NK)

Relapsed/Refractory AML · CD33

#CD33#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleMersana TherapeuticsPhase 3

Upifitimab rilsodotin (Upifitimab rilsodotin)

High Grade Serous Ovarian Cancer; Fallopian Tube Cancer · High Grade Serous Ovarian Cancer

#HighGradeSerousOvarianCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleClinica Universidad de Navarra,…Phase 2

nivolumab (Opdivo, Urelumab + Nivolumab)

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Use of sunitinib, bevacizumab, or sorafenib (Use of sunitinib, bevacizumab, or sorafenib)

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
ADCBiologicstaleVelaVigo Bio IncPhase 2

VBC101 (VBC101)

Participants With Advanced Solid Tumor Malignancies · Participants With Advanced Solid Tumor M

#ParticipantsWithAdvancedSolidTum#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleVelaVigo Bio IncPhase 2

VBC103 (VBC103)

Participants With Advanced Solid Tumor Malignancies · Participants With Advanced Solid Tumor M

#ParticipantsWithAdvancedSolidTum#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstaleVor BiopharmaPhase 2

VCAR33 (VCAR33)

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 DISCONTINUED
CGTBiologicstaleDing-Wei YePhase 2

VG161 via Intravesical Instillation (VG161 via Intravesical Instillation)

NMIBC · NMIBC

#NMIBC#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTAAVBiologicstaleNational Institute of Allergy a…Phase 1

AAV8-VRC07 (VRC-HIVAAV070-00-GT, VRC-HIVAAV070-00-GT (AAV8-VRC07))

HIV-1 Infected Adults With Controlled Viremia · HIV-1 Infected Adults With Controlled Vi

#HIV-1InfectedAdultsWithControlle#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
AntibodystaleNational Institute of Allergy a…Phase 1

VRC-HIVMAB0121-00-AB (VRC-HIVMAB0121-00-AB)

HIV Infection · HIV Infection

#HIVInfection#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMedPacto, Inc.Phase 2

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent

#UrothelialCarcinomaRecurrent#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleSanofiApproved

Vanicream- Dupilumab-naïve (Vanicream- Dupilumab-naïve)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSanofiApproved

Vanicream- Experienced Dupilumab (Vanicream- Experienced Dupilumab)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#항체#면역항체+3
효능 ORR 7%임상시험 1상태 RECRUITING
AntibodystaleFudan UniversityPhase 2

Vebrekotuzumab (Vebrekotuzumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity of California, San F…Phase 1

Velcade (Velcade, Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide, bortezomib)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleEli Lilly and CompanyPhase 3

Vepugratinib (Vepugratinib)

Carcinoma, Transitional Cell; Urinary Bladder Neoplasms · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING

161 / 177 페이지

← 이전다음 →